In the United States, only approximately 0.4% of all melanomas are diagnosed in patients aged <20 years. To the authors' knowledge, melanoma in pediatric members of melanoma-prone families has not been fully investigated to date. The objective of the current study was to evaluate pediatric patients with melanoma with extensive follow-up in melanoma-prone families with and without cyclin-dependent kinase inhibitor 2A (CDKN2A) mutations. METHODS: For this non-population-based study, families were followed prospectively for up to 40 years. A total of 60 families with ≥ 3 patients with melanoma were included for analysis: 30 CDKN2A mutation-positive (CDKN2A+) and 30 CDKN2A mutation-negative (CDKN2A-) families. Age at the time of first melanoma and number of melanomas were obtained for each patient and summarized by family or sets (CDKN2A + vs CDKN2A-). For set comparisons and categorical variables (occurrence of melanoma in pediatric patients, number of melanomas, number of patients with single or multiple melanomas), the Pearson chi-square or Fisher exact test was used. RESULTS: Regardless of CDKN2A status, melanoma-prone families were found to have 6-fold to 28-fold higher percentages of patients with pediatric melanoma compared with the general population of patients with melanoma in the United States. Within CDKN2A + families, pediatric patients with melanoma were significantly more likely to have multiple melanomas compared with their relatives who were diagnosed at age >20 years (71% vs 38%, respectively; P = .004). CDKN2A + families had significantly higher percentages of pediatric patients with melanoma compared with CDKN2A-families (11.1% vs 2.5%; P = .004). CONCLUSIONS: These observations have implications for the prevention of melanoma as well as clinical care for its early detection. Children in melanoma-prone families should have careful sun protection from an early age and skin surveillance to reduce their risk of melanoma. Cancer 2018;124:3715-3723.
INTRODUCTION
Cutaneous malignant melanoma (CMM) is a potentially fatal form of skin cancer, and is the result of a combination of environmental, host, and genetic factors. [1] [2] [3] Multiple high-risk, intermediate-risk, and low-risk susceptibility genes are linked to CMM, with cyclin-dependent kinase inhibitor 2A (CDKN2A) being the major high-risk susceptibility gene. 4 CDKN2A, a tumor suppressor gene that is located on chromosome 9p21, encodes 2 distinct proteins translated in alternate reading frames, from alternatively spliced transcripts. The alpha transcript encodes p16, a protein that inhibits the cyclin-D1-cyclin-dependent kinase 4 (CDK4) or cyclin D1-CDK6 complex. The p16 protein arrests cell growth at the G 1 stage of the cell cycle, acting as a tumor suppressor. 1, 4 The smaller beta transcript specifies p14 alternate reading frame; this protein induces cell cycle arrest or apoptosis acting through the p53 pathway. Germline mutations in CDKN2A have been found in approximately 20% to 40% of melanoma-prone families worldwide. 1, 4 In the general population of the United States, melanoma is the fifth most common cancer diagnosed in men and the sixth most common in women. The median age at the time of melanoma diagnosis is 64 years, and only approximately 0.4% of all melanomas are diagnosed in patients aged <20 years. 5 The major environmental risk factor for melanoma is exposure to ultraviolet (UV) radiation, either through natural exposure or artificial exposure (usually via tanning beds). Host factors associated with melanoma include fair skin, hair, and eye color; poor tanning ability; and the presence of multiple melanocytic nevi. 1 Compared with the general population, melanoma-prone families have a reduced age at melanoma diagnosis and an increased frequency of multiple primary melanomas (MPMs). 6, 7 However, to the best of our knowledge, the occurrence of melanoma in pediatric members of these families (those aged < 20 years) has not been fully investigated.
The goal of the current study was to evaluate the occurrence and clinical and genetic characteristics of young-onset
Cancer September 15, 2018 (ie, pediatric) melanoma cases with extensive follow-up in melanoma-prone families with and without CDKN2A mutations. A better understanding of pediatric melanoma will help to ensure UV protection from an early age and the classification of nevus status; it also would be useful in decision making regarding surveillance approaches.
MATERIALS AND METHODS
Data for this study were obtained from a non-population-based family study from the Division of Cancer Epidemiology and Genetics at the National Cancer Institute (NCI). Families were ascertained through self-referral or health professional referrals, and were followed prospectively for up to 40 years, starting in the 1970s. For this analysis, eligibility criteria included documented cutaneous melanoma, invasive and/or in situ, in at least 3 family members, with at least 2 of the required patients with melanoma being first-degree relatives. Age at the time of melanoma diagnosis was not a criterion for ascertainment. After initial confirmation of family eligibility, all identified living family members were invited to the National Institutes of Health Clinical Center for detailed skin examinations to document susceptibility phenotypes. If families/individuals could not travel to the National Institutes of Health, we organized field trips near individuals' homes to collect biospecimens, conduct skin examinations, and photograph nevi. Written informed consent for each participant or each participant's guardian for this observational study was obtained before participation under an NCI institutional review boardapproved protocol (NCI 02-0211; ClinicalTrials.gov identifier NCT00040352). Willing participants provided blood primarily for genetic studies. All participating families were white and resided in various regions of the United States. Variables collected and examined in the current study included sex, study period, age at the time of melanoma diagnosis, melanoma subtype and site, melanoma thickness, precursor nevus status, number of melanomas, and CDKN2A mutation status. The study period for the time of melanoma occurrence was defined as "retrospective" if the melanoma occurred in a study participant before the participant's initial clinical examination and "prospective" if the melanoma occurred after the initial clinical examination of the participant. All diagnoses of melanoma were confirmed by review of pathology materials/reports, medical records, or death certificates. All melanoma diagnoses were confirmed using the above review strategy except for one pediatric patient (patient 23 from family D7) for whom it was not possible to retrieve medical records or a death certificate. A total of 60 families were included in the current study, 30 of which were CDKN2A mutation positive (denoted as CDKN2A+) and 30 of which were CDKN2A mutation negative (denoted as CDKN2A-). These 60 families included > 1300 clinically evaluated participants (patients with melanoma, unaffected relatives, and spouses).
The NCI's Surveillance, Epidemiology, and End Results (SEER) program was used to obtain data regarding the general population (https://seer.cancer. gov/statfacts/html/melan.html; https://seer.cancer.gov/ csr/1975_2014) 5 of patients with melanoma for comparison with the percentage of pediatric patients with melanoma and age at diagnosis in the melanoma-prone families.
The median age at the time of first diagnosis of melanoma and the number of melanomas were obtained for each individual with melanoma and then summarized by family or sets of families (CDKN2A + vs CDKN2A-).
Statistical Analysis
For comparisons between sets of families (CDKN2A + vs CDKN2A-families; patients with melanoma from CDKN2A + vs CDKN2A-families) and different categorical variables (occurrence of melanoma in pediatric patients, number of melanomas, number of patients with single or multiple melanomas), the Pearson chi-square or Fisher exact test was used depending on sample sizes. Because of the relatively small number of patients available for analysis, we assumed independence of patients with melanoma within families for patient-level analyses. As a sensitivity analysis to reduce the effects of bias from family referral, selection, or correlation, we performed the same comparisons after exclusion of the probands (the patients with melanoma who led to ascertainment of a family) from each family. All statistical analyses were conducted using Excel (Microsoft Corporation, Redmond, Washington), Stata/SE (version 11.2; StataCorp LLC, College Station, Texas), or SAS (version 9.4; SAS Institute Inc, Cary, North Carolina) statistical software. All P values were 2-sided and considered statistically significant at the .05 level.
RESULTS
Among the 60 families (30 of which were CDKN2A + and 30 of which were CDKN2A-) in the current study, there were 311 confirmed patients with melanoma, 24 of whom (7.7%) were diagnosed before age 20 years. Table 1 shows the clinical characteristics of the 24 pediatric patients with melanoma, 21 of whom were from 13 CDKN2A + families and 3 of whom were from 3 CDKN2A-families. All pediatric patients with melanoma from CDKN2A + families for whom biologic specimens were available (19 patients) carried Cancer September 15, 2018 their respective family's mutation. The median age at the time of the first melanoma diagnosis was 16.5 years (range, 9-19 years). Thirteen patients (54%) were female. For the majority of patients (16 of 20 patients with a known classification), the first melanoma was a superficial spreading melanoma; greater than one-half of the melanomas had a precursor nevus, the clear majority being a dysplastic nevus (DN). Overall, the 24 pediatric patients had a median of 2 melanomas (range, 1-32 melanomas over the course of follow-up). Fifteen patients, all from CDKN2A + families, had MPMs. Seven of the 15 patients with MPMs had multiple melanomas before age 20 years. Table 2 shows the age at diagnosis, melanoma thickness, study period, and nevus status for each melanoma, and clinical DN and age at the time of last follow-up for the 24 pediatric patients with melanoma. Similar to the situation for first melanomas, the majority of subsequent melanomas also had precursor lesions (67 of 83 melanomas; 80.7%) with approximately 70% being DN. Among the 21 examined patients, all but 1 patient (patient 21) had clinical DN. However, this patient had small atypical nevi that did not meet the criteria for DN. For 5 patients (patients 2, 4, 15, 19, and 21), their first tumor was melanoma in situ. Two of these patients (patients 19 and 21) had not developed any additional melanomas at the time of last follow-up, although both still were young (ages 22 and 33 years, respectively, at the time of last follow-up) and therefore may develop additional melanomas in the future. Of the 15 patients with MPM, approximately one-half developed additional melanomas at least 10 years after diagnosis of their initial melanomas. Three patients (patients 2, 5, and 10) were diagnosed with > 10 melanomas, invasive or in situ, during their follow-ups of > 30 years. It is interesting to note that the 2 patients who developed the most melanomas used tanning beds during part of the follow-up period. 8 Among the 60 families evaluated, 43% of the CDKN2A + families had at least 1 pediatric CMM case and 10% of CDKN2A-families had at least 1 pediatric CMM case (Table 3) . Furthermore, one-third of CDKN2A + families (10 of 30 families) had pediatric patients with CMM who developed MPMs. In contrast, no CDKN2A-families had pediatric patients with MPM. Approximately 11% of the patients with CMM in CDKN2A + families (21 of 189 patients) and 2.5% of patients with CMM in CDKN2A-families (3 of 122 patients) were diagnosed before age 20 years (Table 3) . Although these percentages differed significantly (P = .004), both percentages were substantially greater than those in the US general population (0.4% occurring in patients diagnosed before age 20 years). 5 Specifically, the melanoma-prone families in this study had 6-fold to 28-fold (2.5/0.4 for pediatric patients with melanoma from CDKN2A-families and 11.1/0.4 for pediatric patients with melanoma from CDKN2A + families) higher percentages of patients with pediatric melanoma compared with the NCI's SEER-based melanoma patient population. 5 The sensitivity analyses excluding probands demonstrated results similar to analyses that included all patients with melanoma (including probands), with significant differences noted between family sets for the pediatric cases (Table 3) . Finally, within CDKN2A + families, pediatric patients with melanoma were significantly more likely to have MPM than their relatives who were diagnosed at age >20 years (71% vs 38%, respectively; P = .004).
DISCUSSION
Cutaneous melanoma is predominantly an adult-onset disease with a median age at diagnosis of 64 years in the United States. 5 Pediatric melanoma, defined herein as that occurring before age 20 years, is rare and reported to occur in only approximately 0.4% of patients with melanoma in the United States. In contrast, regardless of CDKN2A mutation status, the melanoma-prone families in the current study had 6-fold to 28-fold higher percentages of patients with pediatric melanoma compared with the NCI's SEERbased melanoma patient population. 5 Moreover, in the general population, melanoma occurring in this age range demonstrates a female predominance, whereas in the families herein, the occurrence of pediatric melanoma was close to equal in both sexes. 5, 9 In addition, approximately 71% of pediatric patients with melanoma in the CDKN2A + families had multiple melanomas, with nearly one-half of these patients (7 of 15 patients) having multiple melanomas before age 20 years. Pediatric patients with melanoma from CDKN2A + families also were significantly more likely than their nonpediatric melanoma relatives (ie, those diagnosed at age ≥20 years) to have multiple melanomas. This observation is consistent with what has been noted in the general population of patients with melanoma, in which individuals who develop melanoma at an early age also are at higher risk of developing subsequent melanomas compared with older individuals. The risk of second primary melanoma in individuals aged <30 years is increased 15.4-fold; in those aged 30 to 49 years, this risk is increased by 9.6-fold and in those aged >50 years, this risk is increased 8-fold. 10 The incidence of cutaneous melanoma has continued to rise in the United States for the past several Abbreviations: DN, dysplastic nevus; MIS, melanoma in situ. a Clinical nevus indicates that on a previous examination or by history, a nevus was present but was not detected in the pathology report. b Patient was a proband (ie, one of the patients with melanoma who led to ascertainment of the family).
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Cancer September 15, 2018 decades, with an increasing incidence noted in young-onset melanoma in recent years. 5, 11, 12 Among patients diagnosed before age 20 years, the clear majority (>90%) are diagnosed during their teen years, 13 similar to what was observed in the melanoma-prone families in the current study. Although numerous studies have investigated the prevalence of CDKN2A mutations in cases of adult-onset melanoma from families and the general population, [14] [15] [16] [17] [18] to our knowledge less is known regarding the prevalence of these mutations in patients with young-onset melanoma. A study using the Swedish Cancer Registry evaluated 51 patients with histopathologically confirmed melanoma who were diagnosed before age 20 years for germline mutations in CDKN2A and found only 1 CDKN2A mutation in a patient with a strong family history of melanoma. 19 A recent study of 23 clinic-based American, Spanish, and Dutch patients with melanoma who were diagnosed before age 20 years found no germline mutations in the known melanoma-predisposing genes, including CDKN2A. 13 Although based on relatively small numbers, these studies suggest that germline CDKN2A mutations are rare in pediatric patients with melanoma outside of the familial melanoma setting. The current study could not evaluate the prevalence of CDKN2A mutations in pediatric patients with melanoma from the general population but demonstrated that melanoma-prone families, with and without CDKN2A mutations, have an increased frequency of pediatric melanoma compared with the general population of patients with melanoma.
All but one of the pediatric melanomas in the current study were confirmed by review of pathology material/reports, medical records, or death certificates. For the pediatric patient with melanoma from family D7 (patient 23), it was not possible to confirm her melanoma diagnosis because we were unable to obtain medical records or a death certificate. The exclusion of this patient and her family from the study appeared to have a minimal effect on the results. Family U was included among the families without a CDKN2A mutation. The pediatric patient with melanoma in this family was diagnosed at age 12 years. His father was diagnosed with melanoma at age 23 years and his paternal grandmother was diagnosed at age 36 years. The paternal grandmother was negative for a CDKN2A mutation. However, the unaffected paternal grandfather, who self-identified as Latino, carried a CDKN2A variant p.I49T that has conflicting interpretations of pathogenicity (ClinVar 20 ) and occurs at an allele frequency in the Latino population from gnomAD (0.0044) that is above the threshold considered too common to plausibly cause disease. 21, 22 Therefore, this variant was excluded from consideration as diseasecausing and family U was considered to be CDKN2A-for this (and all our previous) studies.
In general, melanocytic neoplasms in children (diagnosed before age 20 years) have been classified into 3 main subtypes: 1) in association with a large congenital melanocytic nevus; 2) spitzoid melanocytic tumors that include spitzoid melanoma and atypical Spitz tumors; and 3) adult-like (or "conventional") melanoma. 9, 13 The majority of melanomas developing in pediatric subjects after puberty, designated as adolescents, tend to demonstrate clinical features consistent with adult melanoma. 9, 23 Approximately 25% of the pediatric patients with melanoma in the current study developed their initial melanomas before/during puberty, with the youngest patient diagnosed at age 9 years; however, all the melanoma tumors in pediatric patients were adult-like with regard to their clinical and histologic characteristics, with the predominant histologic type being superficial spreading melanoma. Furthermore, approximately one-quarter of the initial tumors were melanoma in situ/microinvasive and thus were associated with an excellent prognosis, whereas one-quarter were at least 1.50-mm thick (with 3 being > 2-mm thick) with a much less favorable prognosis. Children in melanoma-prone families should be protected from UV exposure from birth to reduce their risk of melanoma. Furthermore, given the earliest diagnosis of melanoma at only 9 years of age in the current study, regular skin surveillance including the scalp for the early detection of features associated with an increased risk of melanoma, including occurrence of DN, should be considered for children from melanoma-prone families before they enter their teen years. 23, 24 Usually, the first indication that children may develop DN is an increased number of nevi, some of which may be slightly irregular in outline or variable in color. Anecdotally, dysplastic nevi may become more apparent around the time of puberty. Some of these pediatric patients also continue to develop melanomas throughout their lives and therefore need to practice sun protection, carefully monitor their skin for changes both in nevi and normal skin that occur in a manner worrisome for melanoma, and continue to have regular professional skin surveillance throughout their lives.
The issue of whether children from melanoma-prone families should undergo genetic testing is complicated. In a position paper published in 2015, the American Society of Human Genetics recommended the use of predictive genetic testing in minors only for conditions for which a
Cancer September 15, 2018 clinical intervention could be delivered in childhood and for which the benefits of early intervention outweighed potential psychological harms. 25, 26 Stump et al 26 recently investigated whether genetic counseling and test reporting for CDKN2A mutations improved sun protection without inducing distress. In a very small initial study of 9 carriers and 9 noncarriers, the authors reported significantly fewer sunburns and a greater percentage of individuals reporting sun protection adherence between baseline and 1 year after disclosure. However, the results did not differ by mutation status, thereby suggesting that the education provided during the counseling session may have itself contributed toward the changes in behavior. Although the authors suggested that this small initial study provided support for the clinical usefulness of genetic testing and counseling for melanoma risk among minors from families with known familial predisposition mutations, they also noted the importance of confirming the findings in a much larger sample. 26 Although mutation-positive members of CDKN2A + families have an increased risk of melanoma, we recently reported that among American and Swedish CDKN2A + families, members who tested negative for their family's mutation remained at a moderately increased risk of melanoma. 27 Therefore, mutation-negative family members also should be encouraged to follow sun safety recommendations and practice skin self-examination in addition to being considered for continuing dermatologic surveillance. 27 Given that the occurrence of pediatric melanoma in both CDKN2A + and CDKN2A-families in the current study was found to be significantly increased compared with the general population of patients with melanoma in the United States, education and counseling plus skin surveillance for the prevention/early detection of melanoma may be the most important proposed strategies for children in melanoma-prone families. The current study was not population-based and therefore might be prone to referral bias. It also was limited by the relatively small number of patients with melanoma who were diagnosed before age 20 years. Given the relatively small number of pediatric patients with melanoma, analyses comparing patients with melanoma in families with and without CDKN2A mutations were conducted assuming independence of these patients. However, the results were similar, with (patient-based) or without (family-based) this independence assumption. To reduce any effects of bias from family referral, selection, or correlation, we conducted a sensitivity analysis from which the patients with melanoma who led to the ascertainment of each family (ie, the probands) were excluded. The sensitivity analyses demonstrated results that were consistent with the full analyses, suggesting that ascertainment did not bias the results. Because this study was a non-population-based family study, it was not possible to examine the prevalence of CDKN2A mutations in pediatric patients with melanoma from the general population. Large population-based studies would be required for such an evaluation.
The occurrence of pediatric melanoma is significantly increased in melanoma-prone families, with and without CDKN2A mutations, compared with the general population of melanoma patients in the United States. These observations have implications for the prevention of melanoma as well as clinical care for its early detection. Children in melanoma-prone families should have careful sun protection from an early age and skin surveillance to reduce their risk of melanoma. 
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